SCHEMBL4382409

SCHEMBL4382409

COc1cc2c(Nc3ccc4[nH]ncc4c3)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 8/20 0.72
EGFR P00533 10/20 0.71
RET P07949 3/20 0.70
KDR P35968 7/20 0.69
EPHB4 P54760 2/20 0.69
LCK P06239 2/20 0.69
MET P08581 2/20 0.69
MAPT P10636 2/20 0.69
LTK P29376 2/20 0.69
TNK2 Q07912 2/20 0.69
MAP4K5 Q9Y4K4 2/20 0.69
BRAF P15056 2/20 0.69
CIT O14578 1/20 0.69
GAK O14976 1/20 0.69
EPHB6 O15197 1/20 0.69
ABCC4 O15439 1/20 0.69
DAPK3 O43293 1/20 0.69
RIPK2 O43353 1/20 0.69
NR1I2 O75469 1/20 0.69
RPS6KA4 O75676 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4379466 0.94 SRC (0.72) SRCEGFRRETKDREPHB4
SCHEMBL4387083 0.87 SRC (0.72) SRCEGFRRETKDREPHB4
Hydrochloric Acid SCHEMBL4373085 0.87 SRC (0.72) SRCEGFRRETKDREPHB4
Hydrochloric Acid SCHEMBL4379495 0.85 SRC (0.74) SRCEGFRRETKDREPHB4
SCHEMBL19154598 0.84 SRC (0.80) SRCEGFRRETKDREPHB4
SCHEMBL21136951 0.84 ROCK2 (0.81) SRCEGFRRETKDREPHB4
SCHEMBL3531151 0.84 SRC (0.86) SRCEGFRRETKDREPHB4
SCHEMBL6181034 0.84 RET (1.00) EGFRRETKDRLCKGAK
SCHEMBL22383954 0.83 EGFR (0.86) SRCEGFRRETKDREPHB4
SCHEMBL11304 0.83 EGFR (0.86) SRCEGFRRETKDREPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR SRC 1517/4885EGFR 500/4885RET 637/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 SRC 1276/4885EGFR 549/4885RET 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.